From: Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions?
 | WHO | EGIR | NCEP ATP III | AHA | IDF | JIS |
---|---|---|---|---|---|---|
Definitions | insulin resistance together with two or more of the following: | Insulin resistance or impaired fasting glucose (IFG) plus two of the following: | Three or more of the following five risk factors: | Three or more of the following five risk factors: | Central obesity plus 2 other features | Three or more of the following five risk factors: |
Fasting plasma glucose | __ | ≥ 6.1 mmol/l (110 mg/dl) but non-diabetic | ≥ 6.1 mmol/l (110 mg/dl) | ≥ 5.6 mmol/l (100 mg/dl) | ≥ 5.6 mmol/l (100 mg/dl) or diagnosed type 2 diabetes | ≥ 5.6 mmol/l (100 mg/dl) |
Central obesity | Men: waist-hip ratio > 0.90 | Men: waist circumference ≥ 94 cm | Men: waist circumference > 102 cm | Men: waist circumference > 102 cm | Men: waist circumference ≥ 94 cm, | Ethnic cut point for waist circumferencea |
Women: waist-hip ratio > 0.85 and/or BMI > 30 kg/m2 | Women: waist circumference ≥ 80 cm | Women: waist circumference > 88 cm | Women: waist circumference > 88 cm | Women: waist circumference ≥ 80 cma or BMI > 30 kg/m2 | ||
Blood pressure | ≥ 140/90 mmHg | ≥ 140/90 mmHg or treatment | ≥ 130/85 mmHg | ≥130/85 mmHg | ≥ 130/85 mmHg or treatment | ≥ 130/85 mmHg |
Triglycerides | ≥ 1.7 mmol/l (150 mg/dl) | > 2.0 mmol/l (178 mg/dl) | ≥1.7 mmol/l (150 mg/dl) or treatment | ≥1.7 mmol/l (150 mg/dl) or treatment | ≥1.7 mmol/l (150 mg/dl) or treatment | ≥ 1.7 mmol/l (150 mg/dl) or treatment |
HDL-cholesterol | Men: < 0.9 mmol/l (35 mg/dl) | < 1.0 mmol/l (39 mg/dl) or treatment | Men: < 1.03 mmol/l (40 mg/dl) | Men: < 1.03 mmol/l (40 mg/dl) | Men: <1.0 mmol/l (39 mg/dl) | Men: < 1.03 mmol/l (40 mg/dl) |
Women: < 1.0Â mmol/l (39Â mg/ dl) | Women: < 1.29Â mmol/l (50Â mg/ dl) | Women: < 1.29Â mmol/l (50Â mg/dl) | Women: <1.3Â mmol/l (40Â mg/dl) or treatment | Women: < 1.29Â mmol/l (50Â mg/dl) |